Kymera Therapeutics, Inc.
KYMR
Κατάταξη σε μετοχές
#2180
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Τιμή μετοχής
$114.06
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$9.38B
Αλλαγή (1 ημέρα)
5.54%
Αλλαγή (1 έτος)
95.57%
Χώρα
US
Εμπόριο Kymera Therapeutics, Inc. (KYMR)
Κατηγορία
Healthcare
Δείκτης P/B για Kymera Therapeutics, Inc. (KYMR)
Δείκτης P/B στις October 2026 TTM: 6.95
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Kymera Therapeutics, Inc., ο τρέχων δείκτης P/B (TTM) είναι 6.95. Στο τέλος του 2023, η εταιρεία είχε P/B δείκτη 3.76.
Ιστορικό P/B για την Kymera Therapeutics, Inc. από 2018 έως 2026
Δείκτης P/B στο τέλος κάθε έτους
| Έτος | Δείκτης P/B | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 6.95 | 92.50% |
| 2024 | 3.61 | -3.97% |
| 2023 | 3.76 | 36.99% |
| 2022 | 2.75 | -58.57% |
| 2021 | 6.63 | -31.88% |
| 2020 | 9.73 | -148.89% |
| 2019 | -19.91 | -53.72% |
| 2018 | -43.01 | 0.00% |
Δείκτης P/B για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Δείκτης P/B | Διαφορά Δείκτη P/B | Χώρα |
|---|---|---|---|
| 6.251 | -10.05% |
US
|
|
| 13.2547 | 90.73% |
US
|
|
| 4.208 | -39.45% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -11.04% |
NL
|
